Shahar Keinan
Chief Scientific Officer and Cofounder at Cloud Pharmaceuticals
Background
Dr.
Shahar Keinan, Ph.D., co-founded Cloud Pharmaceuticals, Inc., in 2009
and serves as its Chief Scientific Officer. Dr. Keinan has extensive
experience in the field of computational and theoretical chemistry. She
has been instrumental in the development of the novel Inverse Design
technology since its inception at Duke University, and has pioneered the
use of the Inverse Design algorithm to optimize electro-optical
materials and protein inhibitors. She has published
LINKShttp://www.cloudpharmaceuticals.com/dr-shahar-keinan.html
https://www.linkedin.com/in/shahar-keinan-9b729b1
https://www.facebook.com/shahar.keinan.5/about
https://plus.google.com/104847823339870075169/about
Dr. Shahar Keinan
Shahar Keinan, Ph. D.
Chief Scientific Officer (CSO) and CofounderShahar Keinan is the Chief Scientific Officer and co-founder of Cloud Pharmaceuticals. She has over 20 years of extensive experience in the field of computational and theoretical chemistry. Shahar has received a Ph.D. in theoretical chemistry from The Hebrew University of Jerusalem and has numerous papers and presentations in the fields of in-silico drug design and discovery, as well as molecular materials design and computational methods development.Shahar has been instrumental in the development of the novel Quantum Molecular Design process since its inception at Duke University, and has pioneered the use of the Quantum Molecular Design algorithm to optimize electro-optical materials and protein inhibitors. Currently, she leads the development and deployment of Quantum Molecular Design and oversees the technical staff of Cloud Pharmaceuticals.esign and computational methods development.
Shahar has been instrumental in the development of the novel Quantum Molecular Design process since its inception at Duke University, and has pioneered the use of the Quantum Molecular Design algorithm to optimize electro-optical materials and protein inhibitors. Currently, she leads the development and deployment of Quantum Molecular Design and oversees the technical staff of Cloud Pharmaceuticals.
Chief Scientific Officer (CSO) and CofounderShahar Keinan is the Chief Scientific Officer and co-founder of Cloud Pharmaceuticals. She has over 20 years of extensive experience in the field of computational and theoretical chemistry. Shahar has received a Ph.D. in theoretical chemistry from The Hebrew University of Jerusalem and has numerous papers and presentations in the fields of in-silico drug design and discovery, as well as molecular materials design and computational methods development.Shahar has been instrumental in the development of the novel Quantum Molecular Design process since its inception at Duke University, and has pioneered the use of the Quantum Molecular Design algorithm to optimize electro-optical materials and protein inhibitors. Currently, she leads the development and deployment of Quantum Molecular Design and oversees the technical staff of Cloud Pharmaceuticals.esign and computational methods development.
Shahar has been instrumental in the development of the novel Quantum Molecular Design process since its inception at Duke University, and has pioneered the use of the Quantum Molecular Design algorithm to optimize electro-optical materials and protein inhibitors. Currently, she leads the development and deployment of Quantum Molecular Design and oversees the technical staff of Cloud Pharmaceuticals.
Experience
Chief Scientific Officer and Cofounder
Cloud Pharmaceuticals
Cloud
Pharmaceuticals (previously TeraDiscoveries, Inc.) designs new drugs
and drug candidates and accelerates the development process by
implementing new, innovative cloud computing technology in place of
traditional methods.
Cloud Pharmaceuticals
Theory Staff Scientist at the UNC EFRC
University of North Carolina at Chapel Hill
Post-Doctoral fellow
Duke University
Inter-protein electron transfer
Inverse design of NLO materials
Inverse design of drugs
With Prof. Weitao Yang and Prof. David N. BeratanInverse design of NLO materials
Inverse design of drugs
Preformed theoretical design of organic molecules with high non-linear optical response (hyperpolarizability) properties, using inverse design methodologies.
Designed quinoid inhibitors for Cdc25 phosphatase, with potential as cancer drugs.
Post-Doctoral Fellow
Northwestern University
Design of NLO materials
Theoretical Chemistry group
With Prof. Mark Ratner
Collaborating with the experimental group of Prof. Tobin Marks
Department of Chemistry
Theoretical Chemistry group
With Prof. Mark Ratner
Collaborating with the experimental group of Prof. Tobin Marks
Department of Chemistry
Education
The Hebrew University
PhD, Chemistry
Advisor: Prof. David Avnir
Thesis title: “The Applications of the Continuous Symmetry and Chirality Measures”
Thesis title: “The Applications of the Continuous Symmetry and Chirality Measures”
Honors & Awards
Additional Honors & Awards
2002 The Junior Researcher Award from the Lise-Meitner Minerva Center, Israel.2001 The R. Levine Prize of the Israeli Chemical Society for outstanding chemistry graduate.
1994 The Kenet Prize for Educational Merit in Undergraduate studies.
No comments:
Post a Comment